Начало・Списък с акции・Insmed

Insmed

Затворен

СекторЗдравеопазване

98.72 0.46

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

96.22

Максимум

99.38

Ключови измерители
By Trading Economics
Приходи	165M -164M
Продажби	42M 306M
EPS	-0.76
Марж на печалбата	-53.458
Служители	1,664
EBITDA	164M -136M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+100.98% upside

Дивиденти
By Acuity
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-7.5B 23B
Предишно отваряне	98.26
Предишно затваряне	98.72

Настроения в новините

By Acuity

43%

57%

135 / 340 Класиране в Healthcare

Insmed Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 19:16 ч. UTC

Insmed Inc shares are lower today, marking the seventh consecutive session of declines. No specific company news was identified to explain the movement.

31.07.2026 г., 20:06 ч. UTC

Insmed Inc. shares are lower, continuing a seven-session decline amid rising Treasury yields and crude oil prices, with no specific company news identified.

30.07.2026 г., 21:16 ч. UTC

Insmed Inc shares are higher in after-market trading, recovering from earlier losses. The stock rose to a high since Thursday's close.

28.07.2026 г., 19:26 ч. UTC

Insmed Inc shares are lower today, with no specific news identified. Broader market sentiment is bearish, influenced by declines in Asian markets.

27.07.2026 г., 23:41 ч. UTC

Insmed Inc's shares are higher in after-market hours, rebounding from a lower regular session. No specific news was identified for this price movement.

24.07.2026 г., 23:46 ч. UTC

Insmed Inc shares are lower in after-market hours, continuing recent trends. The stock remains near the lower end of its one-month trading range.

22.07.2026 г., 19:11 ч. UTC

Social Media

Insmed shares are lower despite Cantor Fitzgerald's "Overweight" rating and $235 price target, following positive updates on inhalation powder TPIP.

21.07.2026 г., 17:41 ч. UTC

Social Media

News

BMO Capital initiated coverage on Insmed Inc with an Outperform rating and a $192 price target, contributing to the stock's upward movement.

20.07.2026 г., 19:16 ч. UTC

News

Social Media

Insmed Inc's shares are lower today amid declines in the Biotechnology sector. Social media highlights positive sentiment around TPIP data and its strong pipeline.

Сравнение с други в отрасъла

Ценова промяна

Insmed Прогноза

Ценова цел

By TipRanks

100.98% нагоре

12-месечна прогноза

Среден 198.17 USD 100.98%

Висок 243 USD

Нисък 160 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Insmed през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

20 ratings

Купи

Задържане

Продай

Според 20 анализатори, дали борсови рейтинги на Insmed през последните 3 месеца.

Настроение

By Acuity

135 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.